肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2021 ATA指南： 未分化甲状腺癌患者的管理

2021-03-20 美国甲状腺协会 Thyroid . 2021 Mar;3

甲状腺癌

2021年3月，美国甲状腺协会(ATA)发布了 未分化甲状腺癌患者的管理指南。未分化甲状腺癌是一种罕见但致死率较高的甲状腺癌。本文主要针对未分化甲状腺癌患者的管理提供指导建议，内容涉及诊断，

中文标题：

2021 ATA指南： 未分化甲状腺癌患者的管理

英文标题：

2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer

发布机构：

美国甲状腺协会

发布日期：

2021-03-20

简要介绍：

2021年3月，美国甲状腺协会(ATA)发布了 未分化甲状腺癌患者的管理指南。未分化甲状腺癌是一种罕见但致死率较高的甲状腺癌。本文主要针对未分化甲状腺癌患者的管理提供指导建议，内容涉及诊断，初始评估以及治疗方法和监测等，共包含了31条推荐意见和16条最佳实践声明。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 ATA指南： 未分化甲状腺癌患者的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=2b5d21c0020e5a7f, title=2021 ATA指南： 未分化甲状腺癌患者的管理, enTitle=2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer, guiderFrom=Thyroid . 2021 Mar;3, authorId=0, author=, summary=2021年3月，美国甲状腺协会(ATA)发布了 未分化甲状腺癌患者的管理指南。未分化甲状腺癌是一种罕见但致死率较高的甲状腺癌。本文主要针对未分化甲状腺癌患者的管理提供指导建议，内容涉及诊断，, cover=https://img.medsci.cn/2021328/1616864244630_2020535.jpg, journalId=0, articlesId=null, associationId=131, associationName=美国甲状腺协会, associationIntro=内容涉及甲状腺基础与临床研究 ,包括细胞生物学、碘代谢、自身免疫、信号转导、肿瘤发生、基因治疗、流行病学诸方面的内容。, copyright=0, guiderPublishedTime=Sat Mar 20 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年3月，美国甲状腺协会(ATA)发布了&nbsp;未分化甲状腺癌患者的管理指南。未分化甲状腺癌是一种罕见但致死率较高的甲状腺癌。本文主要针对未分化甲状腺癌患者的管理提供指导建议，内容涉及诊断，初始评估以及治疗方法和监测等，共包含了31条推荐意见和16条最佳实践声明。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=865, tagName=甲状腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=23, categoryName=普通外科, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=865, guiderKeyword=甲状腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=20672, appHits=440, showAppHits=0, pcHits=2782, showPcHits=20232, likes=5, shares=16, comments=43, approvalStatus=1, publishedTime=Sun Mar 28 00:59:20 CST 2021, publishedTimeString=2021-03-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun Mar 28 00:57:32 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 22:25:12 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ATA指南： 未分化甲状腺癌患者的管理.pdf)])
2021 ATA指南： 未分化甲状腺癌患者的管理.pdf
下载请点击：
评论区 (36)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2169011, encodeId=e24b216901191, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a65341903, createdName=HYH135135, createdTime=Fri Nov 17 11:51:40 CST 2023, time=2023-11-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2125499, encodeId=9e14212549933, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:22:35 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2089708, encodeId=90472089e080a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37295637389, createdName=ms7000000311570454, createdTime=Thu Sep 22 08:52:29 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198313, encodeId=20071198313bc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e615597068, createdName=ms7000001910826648, createdTime=Tue Mar 01 11:38:12 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189518, encodeId=d173118951864, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Tue Feb 01 01:44:32 CST 2022, time=2022-02-01, status=1, ipAttribution=)]
    2023-11-17 HYH135135 来自四川省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2169011, encodeId=e24b216901191, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a65341903, createdName=HYH135135, createdTime=Fri Nov 17 11:51:40 CST 2023, time=2023-11-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2125499, encodeId=9e14212549933, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:22:35 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2089708, encodeId=90472089e080a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37295637389, createdName=ms7000000311570454, createdTime=Thu Sep 22 08:52:29 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198313, encodeId=20071198313bc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e615597068, createdName=ms7000001910826648, createdTime=Tue Mar 01 11:38:12 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189518, encodeId=d173118951864, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Tue Feb 01 01:44:32 CST 2022, time=2022-02-01, status=1, ipAttribution=)]
    2023-04-12 1471d48dm72暂无昵称 来自安徽省

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2169011, encodeId=e24b216901191, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a65341903, createdName=HYH135135, createdTime=Fri Nov 17 11:51:40 CST 2023, time=2023-11-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2125499, encodeId=9e14212549933, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:22:35 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2089708, encodeId=90472089e080a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37295637389, createdName=ms7000000311570454, createdTime=Thu Sep 22 08:52:29 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198313, encodeId=20071198313bc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e615597068, createdName=ms7000001910826648, createdTime=Tue Mar 01 11:38:12 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189518, encodeId=d173118951864, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Tue Feb 01 01:44:32 CST 2022, time=2022-02-01, status=1, ipAttribution=)]
    2022-09-22 ms7000000311570454

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2169011, encodeId=e24b216901191, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a65341903, createdName=HYH135135, createdTime=Fri Nov 17 11:51:40 CST 2023, time=2023-11-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2125499, encodeId=9e14212549933, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:22:35 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2089708, encodeId=90472089e080a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37295637389, createdName=ms7000000311570454, createdTime=Thu Sep 22 08:52:29 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198313, encodeId=20071198313bc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e615597068, createdName=ms7000001910826648, createdTime=Tue Mar 01 11:38:12 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189518, encodeId=d173118951864, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Tue Feb 01 01:44:32 CST 2022, time=2022-02-01, status=1, ipAttribution=)]
    2022-03-01 ms7000001910826648

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2169011, encodeId=e24b216901191, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a65341903, createdName=HYH135135, createdTime=Fri Nov 17 11:51:40 CST 2023, time=2023-11-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2125499, encodeId=9e14212549933, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:22:35 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2089708, encodeId=90472089e080a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37295637389, createdName=ms7000000311570454, createdTime=Thu Sep 22 08:52:29 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198313, encodeId=20071198313bc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e615597068, createdName=ms7000001910826648, createdTime=Tue Mar 01 11:38:12 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189518, encodeId=d173118951864, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Tue Feb 01 01:44:32 CST 2022, time=2022-02-01, status=1, ipAttribution=)]
    2022-02-01 1de15b39m16(暂无匿称)

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

甲状腺癌基因检测与临床应用广东专家共识（2020版）

暂未更新 · 2020-03-20

妊娠期和产后分化型甲状腺癌促甲状腺激素抑制治疗中国专家共识（2019版）

中国医师协会外科医师分会 · 2020-03-15

2019 专家共识：乐伐替尼治疗甲状腺癌期间不良事件的管理

国外肿瘤科相关专家小组（统称） · 2019-12-13

2019 ESMO临床实践指南：甲状腺癌的诊断，治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2019-09-24

2018 CSCO临床指南：持续/复发及转移性分化型甲状腺癌的诊断和治疗（英文版）

中国临床肿瘤学会(CSCO,Chinese Society of Clinical Oncology) · 2019-02-20

甲状腺癌诊疗规范（2018年版）

中华人民共和国国家卫生健康委员会 · 2018-12-13

拓展阅读

2009 ATA 甲状腺结节和分化型甲状腺癌指南修订版

美国甲状腺协会(ATA,American Thyroid Association) · 2009-12-01

分化型甲状腺癌诊治指南

中国抗癌协会头颈肿瘤外科专业委员会 · 2010-10-01

2012 ESMO临床实践指南：甲状腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2012中国甲状腺结节和分化型甲状腺癌指南

中华医学会内分泌学分会(CSE,Chinese Society of Endocrinology) · 2012-08-08

2012ATA 未分化甲状腺癌管理指南

美国甲状腺协会(ATA,American Thyroid Association) · 2012-11-06

2013 ETA颈部超声扫描和超声引导技术在甲状腺癌患者术后管理中的应用指南

欧洲甲状腺协会(ETA,European Thyroid Association) · 2013-09-05